Long-Term HannaH Data Support Subcutaneous Trastuzumab for Breast Cancer

Patients with HER2-positive early breast cancerwho received subcutaneous trastuzumab had safety and efficacy outcomes that were noninferior to intravenous trastuzumab, a 6-year follow-up analysis of the open-label, prospective, multicenter, phase III, randomized HannaH trial showed (ClinicalTrials.gov identifier: NCT00950300). The long-term trial results were recently published in JAMA Oncology.

Read the full article HERE